Symbols / TEVA Stock $34.43 +4.87% Teva Pharmaceutical Industries Limited
TEVA (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Official websiteTeva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO to treat neurodegenerative and movement disorders chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-05-06 | main | Barclays | Overweight → Overweight | $40 |
| 2026-04-30 | main | JP Morgan | Overweight → Overweight | $40 |
| 2026-04-30 | main | UBS | Buy → Buy | $42 |
| 2026-04-30 | reit | Piper Sandler | Overweight → Overweight | $42 |
| 2026-04-30 | main | Truist Securities | Buy → Buy | $45 |
| 2026-04-09 | main | B of A Securities | Buy → Buy | $42 |
| 2026-03-04 | reit | Piper Sandler | Overweight → Overweight | $41 |
| 2026-02-18 | main | Truist Securities | Buy → Buy | $42 |
| 2026-02-09 | main | Goldman Sachs | Buy → Buy | $45 |
| 2026-01-30 | main | Barclays | Overweight → Overweight | $38 |
| 2026-01-29 | main | Scotiabank | Sector Outperform → Sector Outperform | $40 |
| 2026-01-29 | main | Truist Securities | Buy → Buy | $38 |
| 2026-01-06 | main | Jefferies | Buy → Buy | $40 |
| 2025-12-22 | main | Piper Sandler | Overweight → Overweight | $40 |
| 2025-12-19 | main | Goldman Sachs | Buy → Buy | $35 |
| 2025-12-16 | main | JP Morgan | Overweight → Overweight | $35 |
| 2025-12-09 | main | B of A Securities | Buy → Buy | $32 |
| 2025-12-09 | init | Barclays | — → Overweight | $35 |
| 2025-12-08 | main | Goldman Sachs | Buy → Buy | $31 |
| 2025-12-05 | init | Scotiabank | — → Sector Outperform | $35 |
- Teva Stock Up More Than 100% in a Year: Time to Buy, Hold or Sell? - Yahoo Finance ue, 19 May 2026 07
- Teva (NYSE: TEVA) EVP Shields exercises RSUs, sells 16,195 vested shares - Stock Titan hu, 04 Jun 2026 20
- Teva (TEVA) Launches New Biosimilar Ahzantive in Europe - GuruFocus hu, 04 Jun 2026 14
- Teva Stock Is at Its Highest Level in Nearly a Decade. Here's Why It Could Soar Even More. - The Motley Fool Fri, 15 May 2026 07
- Teva Pharmaceutical Industries Ltd. $TEVA Holdings Lowered by Sound Shore Management Inc. CT - MarketBeat hu, 04 Jun 2026 10
- Teva slides 5% as bearish options flow spikes, with traders weighing deal-related and regulatory crosscurrents - Quiver Quantitative ue, 02 Jun 2026 17
- UroGen Pharma stock reaffirmed at Buy by H.C. Wainwright on Teva settlement - Investing.com Wed, 03 Jun 2026 12
- Teva stock is at its highest level in nearly a decade. Here's why it could soar even more. - MSN hu, 04 Jun 2026 18
- Teva Pharmaceutical Industries (TEVA) Stock Analysis: Exploring a 16.85% Upside Potential - DirectorsTalk Interviews Mon, 01 Jun 2026 09
- Teva Surges 12% — And It's Not Completely Tied To Earnings - Investor's Business Daily Wed, 29 Apr 2026 07
- How Investors May Respond To Teva (TEVA) Pivoting From Generics Toward Higher-Margin Branded Therapies - simplywall.st Wed, 03 Jun 2026 10
- /C O R R E C T I O N -- Veeva Systems/ - PR Newswire Wed, 27 May 2026 13
- New eye drug option in Europe: Teva rolls out Eylea biosimilar AHZANTIVE - Stock Titan hu, 04 Jun 2026 12
- Teva Pharmaceutical Industries Ltd (TEVA) Stock Down 4.5% but St - GuruFocus Wed, 03 Jun 2026 03
- Solid Earnings Reflect Teva Pharmaceutical Industries' (NYSE:TEVA) Strength As A Business - Yahoo Finance Wed, 06 May 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
17,257.00
+4.31%
|
16,544.00
+4.41%
|
15,845.00
+6.16%
|
14,925.00
|
| Operating Revenue |
|
16,834.00
+6.55%
|
15,799.00
+3.43%
|
15,275.00
+5.37%
|
14,497.00
|
| Cost Of Revenue |
|
8,320.00
-1.90%
|
8,481.00
+3.43%
|
8,200.00
+3.12%
|
7,952.00
|
| Reconciled Cost Of Revenue |
|
8,320.00
-1.90%
|
8,481.00
+3.43%
|
8,200.00
+3.12%
|
7,952.00
|
| Gross Profit |
|
8,938.00
+10.84%
|
8,064.00
+5.48%
|
7,645.00
+9.64%
|
6,973.00
|
| Operating Expense |
|
4,986.00
+6.09%
|
4,700.00
+5.59%
|
4,451.00
+3.92%
|
4,283.00
|
| Research And Development |
|
1,013.00
+1.50%
|
998.00
+4.72%
|
953.00
+13.72%
|
838.00
|
| Selling General And Administration |
|
3,973.00
+7.32%
|
3,702.00
+5.83%
|
3,498.00
+1.54%
|
3,445.00
|
| Selling And Marketing Expense |
|
2,686.00
+5.71%
|
2,541.00
+8.78%
|
2,336.00
+3.13%
|
2,265.00
|
| General And Administrative Expense |
|
1,287.00
+10.85%
|
1,161.00
-0.09%
|
1,162.00
-1.53%
|
1,180.00
|
| Other Gand A |
|
1,287.00
+10.85%
|
1,161.00
-0.09%
|
1,162.00
-1.53%
|
1,180.00
|
| Total Expenses |
|
13,306.00
+0.95%
|
13,181.00
+4.19%
|
12,651.00
+3.40%
|
12,235.00
|
| Operating Income |
|
3,952.00
+17.48%
|
3,364.00
+5.32%
|
3,194.00
+18.74%
|
2,690.00
|
| Total Operating Income As Reported |
|
2,157.00
+811.88%
|
-303.00
-169.98%
|
433.00
+119.71%
|
-2,197.00
|
| EBITDA |
|
3,141.00
+304.25%
|
777.00
-50.13%
|
1,558.00
+268.43%
|
-925.00
|
| Normalized EBITDA |
|
4,884.00
+11.41%
|
4,384.00
+2.62%
|
4,272.00
+9.31%
|
3,908.00
|
| Reconciled Depreciation |
|
1,002.00
-5.38%
|
1,059.00
-8.15%
|
1,153.00
-11.85%
|
1,308.00
|
| EBIT |
|
2,139.00
+858.51%
|
-282.00
-169.63%
|
405.00
+118.14%
|
-2,233.00
|
| Total Unusual Items |
|
-1,743.00
+51.68%
|
-3,607.00
-32.90%
|
-2,714.00
+43.84%
|
-4,833.00
|
| Total Unusual Items Excluding Goodwill |
|
-1,743.00
+51.68%
|
-3,607.00
-32.90%
|
-2,714.00
+43.84%
|
-4,833.00
|
| Special Income Charges |
|
-1,794.00
+51.20%
|
-3,676.00
-33.58%
|
-2,752.00
+43.36%
|
-4,859.00
|
| Other Special Charges |
|
467.00
-38.63%
|
761.00
-27.04%
|
1,043.00
-49.59%
|
2,069.00
|
| Impairment Of Capital Assets |
|
1,028.00
-59.77%
|
2,555.00
+137.01%
|
1,078.00
-55.95%
|
2,447.00
|
| Restructuring And Mergern Acquisition |
|
279.00
-25.99%
|
377.00
-42.79%
|
659.00
+61.92%
|
407.00
|
| Net Income |
|
1,410.00
+186.03%
|
-1,639.00
-193.20%
|
-559.00
+77.15%
|
-2,446.00
|
| Pretax Income |
|
1,223.00
+195.25%
|
-1,284.00
-105.77%
|
-624.00
+80.27%
|
-3,163.00
|
| Net Non Operating Interest Income Expense |
|
-985.00
+6.19%
|
-1,050.00
+4.11%
|
-1,095.00
-10.49%
|
-991.00
|
| Interest Expense Non Operating |
|
916.00
-8.58%
|
1,002.00
-2.62%
|
1,029.00
+10.65%
|
930.00
|
| Net Interest Income |
|
-985.00
+6.19%
|
-1,050.00
+4.11%
|
-1,095.00
-10.49%
|
-991.00
|
| Interest Expense |
|
916.00
-8.58%
|
1,002.00
-2.62%
|
1,029.00
+10.65%
|
930.00
|
| Other Income Expense |
|
-1,742.00
+51.57%
|
-3,597.00
-32.10%
|
-2,723.00
+43.96%
|
-4,859.00
|
| Other Non Operating Income Expenses |
|
1.00
-90.00%
|
10.00
+211.11%
|
-9.00
+65.38%
|
-26.00
|
| Gain On Sale Of Security |
|
51.00
-26.09%
|
69.00
+81.58%
|
38.00
+46.15%
|
26.00
|
| Gain On Sale Of Business |
|
-22.00
-246.67%
|
15.00
+400.00%
|
3.00
-93.48%
|
46.00
|
| Tax Provision |
|
-180.00
-126.63%
|
676.00
+9757.14%
|
-7.00
+98.91%
|
-643.00
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
+2200.00%
|
0.00
-95.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
-400.89
+51.68%
|
-829.61
-2956.78%
|
-27.14
+97.19%
|
-966.60
|
| Net Income Including Noncontrolling Interests |
|
1,418.00
+172.38%
|
-1,959.00
-218.54%
|
-615.00
+75.39%
|
-2,499.00
|
| Net Income From Continuing Operation Net Minority Interest |
|
1,410.00
+186.03%
|
-1,639.00
-193.20%
|
-559.00
+77.15%
|
-2,446.00
|
| Net Income From Continuing And Discontinued Operation |
|
1,410.00
+186.03%
|
-1,639.00
-193.20%
|
-559.00
+77.15%
|
-2,446.00
|
| Net Income Continuous Operations |
|
1,418.00
+172.38%
|
-1,959.00
-218.54%
|
-615.00
+75.39%
|
-2,499.00
|
| Minority Interests |
|
-7.00
-102.19%
|
320.00
+471.43%
|
56.00
+5.66%
|
53.00
|
| Normalized Income |
|
2,752.11
+141.75%
|
1,138.39
-46.50%
|
2,127.86
+49.81%
|
1,420.40
|
| Net Income Common Stockholders |
|
1,410.00
+186.03%
|
-1,639.00
-193.20%
|
-559.00
+77.15%
|
-2,446.00
|
| Diluted EPS |
|
1.21
+183.45%
|
-1.45
-190.00%
|
-0.50
+76.42%
|
-2.12
|
| Basic EPS |
|
1.23
+184.83%
|
-1.45
-190.00%
|
-0.50
+76.42%
|
-2.12
|
| Basic Average Shares |
|
1,145.00
+1.24%
|
1,131.00
+1.07%
|
1,119.00
+0.81%
|
1,110.00
|
| Diluted Average Shares |
|
1,163.00
+2.83%
|
1,131.00
+1.07%
|
1,119.00
+0.81%
|
1,110.00
|
| Diluted NI Availto Com Stockholders |
|
1,410.00
+186.03%
|
-1,639.00
-193.20%
|
-559.00
+77.15%
|
-2,446.00
|
| Earnings From Equity Interest Net Of Tax |
|
15.00
+1400.00%
|
1.00
-50.00%
|
2.00
-90.48%
|
21.00
|
| Gain On Sale Of PPE |
|
2.00
+0.00%
|
2.00
-92.00%
|
25.00
+38.89%
|
18.00
|
| Total Other Finance Cost |
|
69.00
+43.75%
|
48.00
-27.27%
|
66.00
+8.20%
|
61.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
40,748.00
+3.62%
|
39,326.00
-9.55%
|
43,479.00
-1.21%
|
44,011.00
|
| Current Assets |
|
13,946.00
+11.11%
|
12,552.00
+0.54%
|
12,485.00
+3.60%
|
12,051.00
|
| Cash Cash Equivalents And Short Term Investments |
|
3,556.00
+7.76%
|
3,300.00
+2.29%
|
3,226.00
+15.17%
|
2,801.00
|
| Cash And Cash Equivalents |
|
3,556.00
+7.76%
|
3,300.00
+2.29%
|
3,226.00
+15.17%
|
2,801.00
|
| Cash Equivalents |
|
2,678.00
+33.57%
|
2,005.00
+17.66%
|
1,704.00
+39.44%
|
1,222.00
|
| Cash Financial |
|
878.00
-32.20%
|
1,295.00
-14.91%
|
1,522.00
-3.61%
|
1,579.00
|
| Receivables |
|
3,709.00
+21.25%
|
3,059.00
-10.24%
|
3,408.00
-7.79%
|
3,696.00
|
| Accounts Receivable |
|
3,709.00
+21.25%
|
3,059.00
-10.24%
|
3,408.00
-7.79%
|
3,696.00
|
| Gross Accounts Receivable |
|
3,790.00
+20.82%
|
3,137.00
-10.45%
|
3,503.00
-7.50%
|
3,787.00
|
| Allowance For Doubtful Accounts Receivable |
|
-81.00
-3.85%
|
-78.00
+17.89%
|
-95.00
-4.40%
|
-91.00
|
| Inventory |
|
3,179.00
+5.72%
|
3,007.00
-25.22%
|
4,021.00
+4.90%
|
3,833.00
|
| Raw Materials |
|
911.00
+4.71%
|
870.00
-26.02%
|
1,176.00
-8.91%
|
1,291.00
|
| Work In Process |
|
364.00
+3.12%
|
353.00
-29.40%
|
500.00
-9.91%
|
555.00
|
| Finished Goods |
|
1,904.00
+6.79%
|
1,783.00
-24.00%
|
2,346.00
+18.07%
|
1,987.00
|
| Prepaid Assets |
|
1,122.00
+11.53%
|
1,006.00
-19.84%
|
1,255.00
+8.00%
|
1,162.00
|
| Assets Held For Sale Current |
|
1,842.00
+4.01%
|
1,771.00
+2430.00%
|
70.00
+600.00%
|
10.00
|
| Other Current Assets |
|
538.00
+31.54%
|
409.00
-19.01%
|
505.00
-8.01%
|
549.00
|
| Total Non Current Assets |
|
26,802.00
+0.10%
|
26,774.00
-13.61%
|
30,993.00
-3.03%
|
31,960.00
|
| Net PPE |
|
4,425.00
-10.57%
|
4,948.00
-19.51%
|
6,147.00
-0.18%
|
6,158.00
|
| Gross PPE |
|
9,153.00
-2.19%
|
9,358.00
-20.59%
|
11,784.00
+0.92%
|
11,676.00
|
| Accumulated Depreciation |
|
-4,728.00
-7.21%
|
-4,410.00
+21.77%
|
-5,637.00
-2.16%
|
-5,518.00
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Land And Improvements |
|
258.00
+21.13%
|
213.00
-13.41%
|
246.00
+0.00%
|
246.00
|
| Buildings And Improvements |
|
2,327.00
+18.24%
|
1,968.00
-20.90%
|
2,488.00
+1.02%
|
2,463.00
|
| Machinery Furniture Equipment |
|
5,846.00
+6.68%
|
5,480.00
-24.16%
|
7,226.00
-1.67%
|
7,349.00
|
| Construction In Progress |
|
377.00
-71.65%
|
1,330.00
-6.80%
|
1,427.00
+19.02%
|
1,199.00
|
| Other Properties |
|
345.00
-5.99%
|
367.00
-7.56%
|
397.00
-5.25%
|
419.00
|
| Goodwill And Other Intangible Assets |
|
19,781.00
+1.10%
|
19,565.00
-13.29%
|
22,564.00
-5.60%
|
23,903.00
|
| Goodwill |
|
16,000.00
+5.63%
|
15,147.00
-11.82%
|
17,177.00
-2.59%
|
17,633.00
|
| Other Intangible Assets |
|
3,781.00
-14.42%
|
4,418.00
-17.99%
|
5,387.00
-14.08%
|
6,270.00
|
| Non Current Deferred Assets |
|
2,191.00
+21.79%
|
1,799.00
-0.72%
|
1,812.00
+24.28%
|
1,458.00
|
| Non Current Deferred Taxes Assets |
|
2,191.00
+21.79%
|
1,799.00
-0.72%
|
1,812.00
+24.28%
|
1,458.00
|
| Other Non Current Assets |
|
405.00
-12.34%
|
462.00
-1.70%
|
470.00
+6.58%
|
441.00
|
| Total Liabilities Net Minority Interest |
|
32,834.00
-2.30%
|
33,606.00
-4.94%
|
35,353.00
-0.17%
|
35,413.00
|
| Current Liabilities |
|
13,456.00
+5.16%
|
12,796.00
+4.48%
|
12,247.00
+6.78%
|
11,469.00
|
| Payables And Accrued Expenses |
|
5,218.00
+4.46%
|
4,995.00
-7.04%
|
5,373.00
+33.06%
|
4,038.00
|
| Payables |
|
2,531.00
+14.89%
|
2,203.00
-15.33%
|
2,602.00
+37.89%
|
1,887.00
|
| Accounts Payable |
|
2,531.00
+14.89%
|
2,203.00
-15.33%
|
2,602.00
+37.89%
|
1,887.00
|
| Current Accrued Expenses |
|
2,687.00
-3.76%
|
2,792.00
+0.76%
|
2,771.00
+28.82%
|
2,151.00
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
739.00
+18.43%
|
624.00
+2.13%
|
611.00
+7.95%
|
566.00
|
| Current Debt And Capital Lease Obligation |
|
1,820.00
+2.19%
|
1,781.00
+6.52%
|
1,672.00
-20.72%
|
2,109.00
|
| Current Debt |
|
1,820.00
+2.19%
|
1,781.00
+6.52%
|
1,672.00
-20.72%
|
2,109.00
|
| Other Current Borrowings |
|
1,820.00
+2.19%
|
1,781.00
+6.52%
|
1,672.00
-20.72%
|
2,109.00
|
| Other Current Liabilities |
|
1,536.00
-10.59%
|
1,718.00
+62.69%
|
1,056.00
+4.97%
|
1,006.00
|
| Total Non Current Liabilities Net Minority Interest |
|
19,378.00
-6.88%
|
20,810.00
-9.94%
|
23,106.00
-3.50%
|
23,944.00
|
| Long Term Debt And Capital Lease Obligation |
|
15,274.00
-6.28%
|
16,298.00
-11.81%
|
18,481.00
-4.99%
|
19,452.00
|
| Long Term Debt |
|
14,986.00
-6.35%
|
16,002.00
-11.89%
|
18,161.00
-4.93%
|
19,103.00
|
| Long Term Capital Lease Obligation |
|
288.00
-2.70%
|
296.00
-7.50%
|
320.00
-8.31%
|
349.00
|
| Tradeand Other Payables Non Current |
|
—
|
—
|
—
|
3,847.00
|
| Non Current Deferred Liabilities |
|
296.00
-38.72%
|
483.00
-20.30%
|
606.00
+10.58%
|
548.00
|
| Non Current Deferred Taxes Liabilities |
|
296.00
-38.72%
|
483.00
-20.30%
|
606.00
+10.58%
|
548.00
|
| Other Non Current Liabilities |
|
3,808.00
-5.49%
|
4,029.00
+0.25%
|
4,019.00
+1.90%
|
3,944.00
|
| Stockholders Equity |
|
7,910.00
+47.22%
|
5,373.00
-28.42%
|
7,506.00
-3.82%
|
7,804.00
|
| Common Stock Equity |
|
7,910.00
+47.22%
|
5,373.00
-28.42%
|
7,506.00
-3.82%
|
7,804.00
|
| Capital Stock |
|
58.00
+0.00%
|
58.00
+1.75%
|
57.00
+0.00%
|
57.00
|
| Common Stock |
|
58.00
+0.00%
|
58.00
+1.75%
|
57.00
+0.00%
|
57.00
|
| Share Issued |
|
1,256.37
+1.25%
|
1,240.84
+1.12%
|
1,227.09
+0.84%
|
1,216.90
|
| Ordinary Shares Number |
|
1,149.81
+1.41%
|
1,133.84
+1.14%
|
1,121.09
+0.92%
|
1,110.90
|
| Treasury Shares Number |
|
106.56
-0.42%
|
107.00
+0.94%
|
106.00
+0.00%
|
106.00
|
| Additional Paid In Capital |
|
28,133.00
+1.33%
|
27,764.00
-0.15%
|
27,807.00
+0.43%
|
27,688.00
|
| Retained Earnings |
|
-13,762.00
+9.30%
|
-15,173.00
-12.11%
|
-13,534.00
-4.31%
|
-12,975.00
|
| Gains Losses Not Affecting Retained Earnings |
|
-2,391.00
+24.05%
|
-3,148.00
-16.72%
|
-2,697.00
+4.97%
|
-2,838.00
|
| Treasury Stock |
|
4,128.00
+0.00%
|
4,128.00
+0.00%
|
4,128.00
+0.00%
|
4,128.00
|
| Minority Interest |
|
4.00
-98.85%
|
347.00
-44.03%
|
620.00
-21.91%
|
794.00
|
| Other Equity Adjustments |
|
-2,391.00
+24.05%
|
-3,148.00
-16.72%
|
-2,697.00
+4.97%
|
-2,838.00
|
| Total Equity Gross Minority Interest |
|
7,914.00
+38.36%
|
5,720.00
-29.61%
|
8,126.00
-5.49%
|
8,598.00
|
| Total Capitalization |
|
22,896.00
+7.12%
|
21,375.00
-16.72%
|
25,667.00
-4.61%
|
26,907.00
|
| Working Capital |
|
490.00
+300.82%
|
-244.00
-202.52%
|
238.00
-59.11%
|
582.00
|
| Invested Capital |
|
24,716.00
+6.74%
|
23,156.00
-15.30%
|
27,339.00
-5.78%
|
29,016.00
|
| Total Debt |
|
17,094.00
-5.45%
|
18,079.00
-10.29%
|
20,153.00
-6.53%
|
21,561.00
|
| Net Debt |
|
13,250.00
-8.51%
|
14,483.00
-12.79%
|
16,607.00
-9.80%
|
18,411.00
|
| Capital Lease Obligations |
|
288.00
-2.70%
|
296.00
-7.50%
|
320.00
-8.31%
|
349.00
|
| Net Tangible Assets |
|
-11,871.00
+16.35%
|
-14,192.00
+5.75%
|
-15,058.00
+6.47%
|
-16,099.00
|
| Tangible Book Value |
|
-11,871.00
+16.35%
|
-14,192.00
+5.75%
|
-15,058.00
+6.47%
|
-16,099.00
|
| Current Provisions |
|
4,143.00
+12.64%
|
3,678.00
+4.05%
|
3,535.00
-5.73%
|
3,750.00
|
| Other Equity Interest |
|
—
|
—
|
1.00
|
—
|
| Other Inventories |
|
—
|
1.00
+200.00%
|
-1.00
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
1,649.00
+32.24%
|
1,247.00
-8.85%
|
1,368.00
-13.96%
|
1,590.00
|
| Cash Flow From Continuing Operating Activities |
|
1,649.00
+32.24%
|
1,247.00
-8.85%
|
1,368.00
-13.96%
|
1,590.00
|
| Net Income From Continuing Operations |
|
1,418.00
+172.38%
|
-1,959.00
-218.54%
|
-615.00
+75.39%
|
-2,499.00
|
| Depreciation Amortization Depletion |
|
1,002.00
-5.38%
|
1,059.00
-8.15%
|
1,153.00
-11.85%
|
1,308.00
|
| Depreciation |
|
421.00
-10.62%
|
471.00
-12.29%
|
537.00
-6.77%
|
576.00
|
| Amortization Cash Flow |
|
581.00
-1.19%
|
588.00
-4.55%
|
616.00
-15.85%
|
732.00
|
| Depreciation And Amortization |
|
1,002.00
-5.38%
|
1,059.00
-8.15%
|
1,153.00
-11.85%
|
1,308.00
|
| Amortization Of Intangibles |
|
581.00
-1.19%
|
588.00
-4.55%
|
616.00
-15.85%
|
732.00
|
| Other Non Cash Items |
|
81.00
-85.54%
|
560.00
+818.03%
|
61.00
+167.03%
|
-91.00
|
| Stock Based Compensation |
|
157.00
+27.64%
|
123.00
+1.65%
|
121.00
-2.42%
|
124.00
|
| Asset Impairment Charge |
|
1,028.00
-59.77%
|
2,555.00
+137.01%
|
1,078.00
-55.95%
|
2,447.00
|
| Deferred Tax |
|
-671.00
-5.84%
|
-634.00
-100.00%
|
-317.00
+70.21%
|
-1,064.00
|
| Deferred Income Tax |
|
-671.00
-5.84%
|
-634.00
-100.00%
|
-317.00
+70.21%
|
-1,064.00
|
| Operating Gains Losses |
|
—
|
-22.00
+46.34%
|
-41.00
-510.00%
|
10.00
|
| Gain Loss On Investment Securities |
|
—
|
—
|
-41.00
-510.00%
|
10.00
|
| Gain Loss On Sale Of PPE |
|
—
|
—
|
—
|
10.00
|
| Change In Working Capital |
|
-1,366.00
-214.02%
|
-435.00
-504.17%
|
-72.00
-105.31%
|
1,355.00
|
| Change In Receivables |
|
-173.00
-170.61%
|
245.00
+1941.67%
|
12.00
-96.41%
|
334.00
|
| Changes In Account Receivables |
|
-173.00
-170.61%
|
245.00
+1941.67%
|
12.00
-96.41%
|
334.00
|
| Change In Inventory |
|
152.00
-8.43%
|
166.00
+212.93%
|
-147.00
+9.82%
|
-163.00
|
| Change In Payables And Accrued Expense |
|
-15.00
-105.81%
|
258.00
-83.75%
|
1,588.00
-21.07%
|
2,012.00
|
| Change In Payable |
|
-15.00
-105.81%
|
258.00
-83.75%
|
1,588.00
-21.07%
|
2,012.00
|
| Change In Account Payable |
|
-15.00
-105.81%
|
258.00
-83.75%
|
1,588.00
-21.07%
|
2,012.00
|
| Change In Other Current Assets |
|
-1,330.00
-20.47%
|
-1,104.00
+27.61%
|
-1,525.00
-84.18%
|
-828.00
|
| Investing Cash Flow |
|
737.00
-6.94%
|
792.00
-18.18%
|
968.00
+47.56%
|
656.00
|
| Cash Flow From Continuing Investing Activities |
|
737.00
-6.94%
|
792.00
-18.18%
|
968.00
+47.56%
|
656.00
|
| Net PPE Purchase And Sale |
|
-501.00
-0.60%
|
-498.00
+5.32%
|
-526.00
+4.01%
|
-548.00
|
| Purchase Of PPE |
|
-501.00
-0.60%
|
-498.00
+5.32%
|
-526.00
+4.01%
|
-548.00
|
| Sale Of PPE |
|
—
|
—
|
—
|
—
|
| Capital Expenditure |
|
-501.00
-0.60%
|
-498.00
+5.32%
|
-526.00
+4.01%
|
-548.00
|
| Net Investment Purchase And Sale |
|
-15.00
+51.61%
|
-31.00
+32.61%
|
-46.00
-1633.33%
|
3.00
|
| Purchase Of Investment |
|
-57.00
+19.72%
|
-71.00
-54.35%
|
-46.00
-4500.00%
|
-1.00
|
| Sale Of Investment |
|
42.00
+5.00%
|
40.00
|
0.00
-100.00%
|
4.00
|
| Net Business Purchase And Sale |
|
34.00
+21.43%
|
28.00
-58.82%
|
68.00
+11.48%
|
61.00
|
| Purchase Of Business |
|
0.00
+100.00%
|
-15.00
|
0.00
+100.00%
|
-7.00
|
| Gain Loss On Sale Of Business |
|
0.00
+100.00%
|
-22.00
+46.34%
|
-41.00
-510.00%
|
10.00
|
| Net Other Investing Changes |
|
5.00
+150.00%
|
2.00
+140.00%
|
-5.00
|
—
|
| Financing Cash Flow |
|
-2,151.00
-20.10%
|
-1,791.00
+6.38%
|
-1,913.00
-28.65%
|
-1,487.00
|
| Cash Flow From Continuing Financing Activities |
|
-2,151.00
-20.10%
|
-1,791.00
+6.38%
|
-1,913.00
-28.65%
|
-1,487.00
|
| Net Issuance Payments Of Debt |
|
-1,814.00
-10.54%
|
-1,641.00
+3.53%
|
-1,701.00
-24.25%
|
-1,369.00
|
| Issuance Of Debt |
|
2,298.00
|
0.00
-100.00%
|
3,151.00
|
0.00
|
| Repayment Of Debt |
|
-4,112.00
-150.58%
|
-1,641.00
+66.18%
|
-4,852.00
-254.42%
|
-1,369.00
|
| Long Term Debt Issuance |
|
2,298.00
|
0.00
-100.00%
|
2,451.00
|
0.00
|
| Long Term Debt Payments |
|
-4,112.00
-150.58%
|
-1,641.00
+60.48%
|
-4,152.00
-203.29%
|
-1,369.00
|
| Net Long Term Debt Issuance |
|
-1,814.00
-10.54%
|
-1,641.00
+3.53%
|
-1,701.00
-24.25%
|
-1,369.00
|
| Short Term Debt Issuance |
|
0.00
|
0.00
-100.00%
|
700.00
|
0.00
|
| Short Term Debt Payments |
|
0.00
|
0.00
+100.00%
|
-700.00
|
0.00
|
| Net Short Term Debt Issuance |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Other Financing Charges |
|
-337.00
-124.67%
|
-150.00
+29.25%
|
-212.00
-79.66%
|
-118.00
|
| Changes In Cash |
|
235.00
-4.86%
|
247.00
-41.61%
|
423.00
-44.27%
|
759.00
|
| Effect Of Exchange Rate Changes |
|
21.00
+112.07%
|
-174.00
-480.00%
|
-30.00
+75.61%
|
-123.00
|
| Beginning Cash Position |
|
3,300.00
+2.26%
|
3,227.00
+13.87%
|
2,834.00
+28.94%
|
2,198.00
|
| End Cash Position |
|
3,556.00
+7.76%
|
3,300.00
+2.26%
|
3,227.00
+13.87%
|
2,834.00
|
| Free Cash Flow |
|
1,148.00
+53.27%
|
749.00
-11.05%
|
842.00
-19.19%
|
1,042.00
|
| Interest Paid Supplemental Data |
|
950.00
-5.38%
|
1,004.00
-6.86%
|
1,078.00
+13.71%
|
948.00
|
| Income Tax Paid Supplemental Data |
|
—
|
471.00
+58.05%
|
298.00
-45.12%
|
543.00
|
| Interest Received CFI |
|
1,214.00
-5.96%
|
1,291.00
-12.59%
|
1,477.00
+29.56%
|
1,140.00
|
| Sale Of Business |
|
34.00
-20.93%
|
43.00
-36.76%
|
68.00
+0.00%
|
68.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-06-04 View
- 42026-06-01 View
- 42026-06-01 View
- 42026-06-01 View
- 42026-06-01 View
- 42026-06-01 View
- 42026-06-01 View
- 42026-06-01 View
- 42026-06-01 View
- 42026-06-01 View
- 8-K2026-05-28 View
- 42026-05-18 View
- 42026-05-18 View
- 42026-05-07 View
- 42026-05-07 View
- 42026-05-04 View
- 42026-05-04 View
- 10-Q2026-04-29 View
- 8-K2026-04-29 View
- 42026-03-19 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|